Wu Shi-Kai, Zhao Xin, Meng Xiang-Ying, DU Meng, Zhang Shao-Hua, Wang Tao, Song San-Tai, Jiang Ze-Fei
Department of Breast Cancer, Academy of Military Medical Sciences, Beijing, China.
Zhonghua Yi Xue Za Zhi. 2012 Nov 13;92(42):3001-3. doi: 10.3760/cma.j.issn.0376-2491.2012.42.014.
To explore the chemotherapeutic efficacies and prognostic factors of metastatic triple-negative breast cancer.
The clinicopathologic data of 151 patients with metastatic triple-negative breast cancer were collected from September 1994 to November 2011 and their clinicopathologic characteristics, recurrence and survival were analyzed.
Platinum plus taxol or vinorelbine was significantly higher than others for these patients (42.1% vs 23.1%, P = 0.022). The median overall survivals of those on first-line chemotherapy with partial remission, stable disease and progressive disease were 29.6, 24.7 and 13.1 months respectively. The differences were statistically significant (P = 0.045). Two or three-line chemotherapy showed no obvious statistical relationship with total overall survival. Simple factor analysis showed that the number of metastasis, visceral metastases and the efficacies of first-line chemotherapy were correlated with overall survival (all P < 0.05). Multivariate Cox regression showed that disease-free survival and the efficacies of first-line chemotherapy were the independent prognostic factors of metastatic triple-negative breast cancer.
The combined chemotherapy of platinum may achieve better efficacies in the treatment of metastatic triple-negative breast cancer. And the efficacies of first-line chemotherapy are closely correlated with survival.
探讨转移性三阴性乳腺癌的化疗疗效及预后因素。
收集1994年9月至2011年11月间151例转移性三阴性乳腺癌患者的临床病理资料，分析其临床病理特征、复发及生存情况。
铂类联合紫杉醇或长春瑞滨对这些患者的疗效显著高于其他方案（42.1%对23.1%，P = 0.022）。一线化疗达到部分缓解、病情稳定和病情进展患者的中位总生存期分别为29.6、24.7和13.1个月。差异有统计学意义（P = 0.045）。二线或三线化疗与总总生存期无明显统计学关联。单因素分析显示转移灶数量、内脏转移及一线化疗疗效与总生存期相关（均P < 0.05）。多因素Cox回归显示无病生存期及一线化疗疗效是转移性三阴性乳腺癌的独立预后因素。
铂类联合化疗在转移性三阴性乳腺癌治疗中可能取得更好疗效。且一线化疗疗效与生存密切相关。
